IP Library Granted Patent US 7,067,627
Granted Patent B2
US 7,067,627 · App. 10/147,603 · Granted Jun 27, 2006

Schizophrenia associated genes, proteins and biallelic markers

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,067,627
App. No.
10/147,603
Granted
Jun 27, 2006
Kind
B2
Abstract

The invention concerns the human sbg1, g34665, sbg2, g35017 and g35018 genes, polynucleotides, polypeptides biallelic markers, and human chromosome 13q31-q33 biallelic markers. The invention also concerns the association established between schizophrenia and bipolar disorder and the biallelic markers and the sbg1, g34665, sbg2, g35017 and g35018 genes and nucleotide sequences. The invention provides means to identify compounds useful in the treatment of schizophrenia, bipolar disorder and related diseases, means to determine the predisposition of individuals to said disease as well as means for the disease diagnosis and prognosis.

Claims (12)

1. A composition comprising an isolated and purified polypeptide comprising the amino acid sequence of SEQ ID NO:232 or an epitope-containing fragment thereof, said fragment consisting of at least 8 contiguous amino acids selected SEQ ID NO:232.

2. The composition of claim 1 , wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:232.

3. The composition of claim 1 , wherein said polypeptide consists of the amino acid sequence of SEQ ID NO:232.

4. The composition of claim 1 , wherein said polypeptide comprises an epitope-containing fragment consisting of at least 8 contiguous amino acids selected from SEQ ID NO:232.

5. A method of making an SBG1 polypeptide, said method comprising the following steps:

a) providing a cell or tissue expressing an SBG1 polypeptide comprising the amino acid sequence shown as SEQ ID NO:232 or an epitope-containing fragment thereof, said fragment consisting of at least 8 contiguous amino acids selected SEQ ID NO:232; and

b) purifying said polypeptide from said cell or said tissue.

6. An isolated polypeptide comprising SEQ ID NO: 232 or an epitope-containing fragment of SEQ ID NO: 232, said fragment consisting of at least 8 contiguous amino acids selected from SEQ ID NO:232.

7. The isolated polypeptide of claim 6 , wherein said polypeptide comprises SEQ ID NO: 232.

8. The isolated polypeptide of claim 6 , wherein said polypeptide comprises an epitope-containing fragment of SEQ ID NO: 232, said fragment consisting of at least 8 contiguous amino acids selected from SEQ ID NO:232.

9. The isolated polypeptide of claim 7 , further comprising a heterologous polypeptide sequence.

10. The isolated polypeptide of claim 8 , further comprising a heterologous polypeptide sequence.

Assignments (3)
CHANGE OF NAME Recorded Aug 3, 2005
From: GENSET S.A.
To: SERONO GENETICS INSTITUTE S.A.
Reel/Frame 016348/0865 →
CHANGE OF ASSIGEE ADDRESS Recorded Aug 25, 2003
From: GENSET S.A.
To: GENSET S.A.
Reel/Frame 013907/0449 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2003
From: COHEN, DANIEL; BLUMENFELD, MARTA; CHUMAKOV, LLYA; BOUGUELERET, LYDIE; BIHAIN, BERNARD; ESSIOUX, LAURENT
To: GENSET, S.A.
Reel/Frame 013877/0276 →